Effect of soy on metabolic syndrome and cardiovascular risk factors : a randomized controlled trial by M. Ruscica et al.
Dear Author,
Here are the proofs of your article.
• You can submit your corrections online, via e-mail or by fax.
• For online submission please insert your corrections in the online correction form. Always
indicate the line number to which the correction refers.
• You can also insert your corrections in the proof PDF and email the annotated PDF.
• For fax submission, please ensure that your corrections are clearly legible. Use a fine black
pen and write the correction in the margin, not too close to the edge of the page.
• Remember to note the journal title, article number, and your name when sending your
response via e-mail or fax.
• Check the metadata sheet to make sure that the header information, especially author names
and the corresponding affiliations are correctly shown.
• Check the questions that may have arisen during copy editing and insert your answers/
corrections.
• Check that the text is complete and that all figures, tables and their legends are included. Also
check the accuracy of special characters, equations, and electronic supplementary material if
applicable. If necessary refer to the Edited manuscript.
• The publication of inaccurate data such as dosages and units can have serious consequences.
Please take particular care that all such details are correct.
• Please do not make changes that involve only matters of style. We have generally introduced
forms that follow the journal’s style.
Substantial changes in content, e.g., new results, corrected values, title and authorship are not
allowed without the approval of the responsible editor. In such a case, please contact the
Editorial Office and return his/her consent together with the proof.
• If we do not receive your corrections within 48 hours, we will send you a reminder.
• Your article will be published Online First approximately one week after receipt of your
corrected proofs. This is the official first publication citable with the DOI. Further changes
are, therefore, not possible.
• The printed version will follow in a forthcoming issue.
Please note
After online publication, subscribers (personal/institutional) to this journal will have access to the
complete article via the DOI using the URL: http://dx.doi.org/[DOI].
If you would like to know when your article has been published online, take advantage of our free
alert service. For registration and further information go to: http://www.link.springer.com.
Due to the electronic nature of the procedure, the manuscript and the original figures will only be
returned to you on special request. When you return your corrections, please inform us if you would
like to have these documents returned.
Metadata of the article that will be visualized in
OnlineFirst
ArticleTitle Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial
Article Sub-Title
Article CopyRight Springer-Verlag Berlin Heidelberg
(This will be the copyright line in the final PDF)
Journal Name European Journal of Nutrition
Corresponding Author Family Name Ruscica
Particle
Given Name Massimiliano
Suffix
Division Dipartimento di Scienze Farmacologiche e Biomolecolari
Organization Università degli Studi di Milano
Address Milan, Italy
Phone +39-02-50318229
Fax
Email massimiliano.ruscica@unimi.it
URL
ORCID http://orcid.org/0000-0002-0195-7061
Corresponding Author Family Name Magni
Particle
Given Name Paolo
Suffix
Division Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e
Biomolecolari
Organization Università degli Studi di Milano
Address Milan, Italy
Phone +39-02-50318229
Fax
Email paolo.magni@unimi.it
URL
ORCID
Author Family Name Pavanello
Particle
Given Name Chiara
Suffix
Division Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e
Biomolecolari
Organization Università degli Studi di Milano
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Gandini
Particle
Given Name Sara
Suffix
Division Division of Epidemiology and Biostatistics
Organization European Institute of Oncology
Address 20146, Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Gomaraschi
Particle
Given Name Monica
Suffix
Division Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e
Biomolecolari
Organization Università degli Studi di Milano
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Vitali
Particle
Given Name Cecilia
Suffix
Division Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e
Biomolecolari
Organization Università degli Studi di Milano
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Macchi
Particle
Given Name Chiara
Suffix
Division Dipartimento di Scienze Farmacologiche e Biomolecolari
Organization Università degli Studi di Milano
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Morlotti
Particle
Given Name Beatrice
Suffix
Division Centro Dislipidemie
Organization A.S.S.T. Grande Ospedale Metropolitano Niguarda
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Aiello
Particle
Given Name Gilda
Suffix
Division Dipartimento di Scienze Farmaceutiche
Organization Università degli Studi di Milano
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Bosisio
Particle
Given Name Raffaella
Suffix
Division Centro Dislipidemie
Organization A.S.S.T. Grande Ospedale Metropolitano Niguarda
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Calabresi
Particle
Given Name Laura
Suffix
Division Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e
Biomolecolari
Organization Università degli Studi di Milano
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Arnoldi
Particle
Given Name Anna
Suffix
Division Dipartimento di Scienze Farmaceutiche
Organization Università degli Studi di Milano
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Author Family Name Sirtori
Particle
Given Name Cesare R.
Suffix
Division Centro Dislipidemie
Organization A.S.S.T. Grande Ospedale Metropolitano Niguarda
Address Milan, Italy
Phone
Fax
Email
URL
ORCID
Schedule
Received 23 June 2016
Revised
Accepted 12 October 2016
Abstract Background:
Cardiovascular diseases are currently the commonest cause of death worldwide. Different strategies for
their primary prevention have been planned, taking into account the main known risk factors, which
include an atherogenic lipid profile and visceral fat excess.
Methods:
The study was designed as a randomized, parallel, single-center study with a nutritional intervention
duration of 12 weeks. Whole soy foods corresponding to 30 g/day soy protein were given in substitution of
animal foods containing the same protein amount.
Results:
The soy nutritional intervention resulted in a reduction in the number of MetS features in 13/26 subjects.
Moreover, in the soy group we observed a significant improvement of median percentage changes for body
weight (−1.5 %) and BMI (−1.5 %), as well as for atherogenic lipid markers, namely TC (−4.85 %), LDL-
C (−5.25 %), non-HDL-C (−7.14 %) and apoB (−14.8 %). Since the majority of the studied variables were
strongly correlated, three factors were identified which explained the majority (52 %) of the total variance
in the whole data set. Among them, factor 1, which loaded lipid and adipose variables, explained the 22 %
of total variance, showing a statistically significant difference between treatment arms (p = 0.002).
Conclusions:
The inclusion of whole soy foods (corresponding to 30 g/day protein) in a lipid-lowering diet significantly
improved a relevant set of biomarkers associated with cardiovascular risk.
Keywords (separated by '-') Soy protein - Lipids - Metabolic syndrome and obesity
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weight (−1.5 %) and BMI (−1.5 %), as well as for ath-
erogenic lipid markers, namely TC (−4.85 %), LDL-C 
(−5.25 %), non-HDL-C (−7.14 %) and apoB (−14.8 %). 
Since the majority of the studied variables were strongly 
correlated, three factors were identified which explained 
the majority (52 %) of the total variance in the whole data 
set. Among them, factor 1, which loaded lipid and adipose 
variables, explained the 22 % of total variance, showing a 
statistically significant difference between treatment arms 
(p = 0.002).
Conclusions The inclusion of whole soy foods (corre-
sponding to 30 g/day protein) in a lipid-lowering diet sig-
nificantly improved a relevant set of biomarkers associated 
with cardiovascular risk.
Keywords Soy protein · Lipids · Metabolic syndrome and 
obesity
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Abstract 
Background Cardiovascular diseases are currently the 
commonest cause of death worldwide. Different strategies 
for their primary prevention have been planned, taking into 
account the main known risk factors, which include an ath-
erogenic lipid profile and visceral fat excess.
Methods The study was designed as a randomized, paral-
lel, single-center study with a nutritional intervention dura-
tion of 12 weeks. Whole soy foods corresponding to 30 g/
day soy protein were given in substitution of animal foods 
containing the same protein amount.
Results The soy nutritional intervention resulted in a 
reduction in the number of MetS features in 13/26 sub-
jects. Moreover, in the soy group we observed a signifi-
cant improvement of median percentage changes for body 
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SBP  Systolic blood pressure
sICAM-1  Soluble intercellular adhesion molecular 1
TC  Total cholesterol
TG  Triglycerides
VFR  Visceral fat rating
WC  Waist circumference
Introduction
Cardiovascular diseases (CVD) are currently the com-
monest cause of death worldwide (WHO January 2015; 
[1]), and different strategies for their primary prevention 
have been planned, taking into account the main known 
risk factors, which include an atherogenic lipid profile and 
abdominal/visceral fat excess [2–4]. Total abdominal adi-
pose tissue may be subdivided into subcutaneous-abdom-
inal compartment and intra-abdominal compartment. This 
latter, also referred to as ‘visceral fat,’ is associated with 
insulin resistance and the specific features of the metabolic 
syndrome (MetS) [5], which also includes the combination 
of dyslipidemia, hyperglycemia or type 2 diabetes mellitus 
and hypertension, in association with insulin resistance and 
systemic inflammation [6, 7].
The biochemical factors involved in increased primary 
CVD risk associated with these features include elevated 
free fatty acid flux to the liver, altered adipokine produc-
tion and altered HDL level and distribution into different 
subclasses [3], resulting in a proatherogenic environment. 
In particular, MetS has been associated with increased 
small HDL-3 and reduced large HDL-2 particles [8]. All 
these risk factors can be a consequence of dietary habits 
and may therefore be influenced by diet and lifestyle modi-
fications. Functional foods [9] and nutraceuticals [10] have 
been assessed in several clinical studies, and meta-analyti-
cal reports have indicated these as effective approaches for 
the management of primary CVD risk in the MetS [11, 12]. 
Within this context, numerous randomized controlled trials 
(RCTs) and some meta-analyses [13, 14] have shown that 
a regular consumption of soy protein improves circulating 
lipid parameters. More specifically, the inclusion of puri-
fied soy protein in the range of 15–40 g/day into the diet 
of adults with normal or moderately elevated total choles-
terol (TC) resulted in a significant reduction in TC (at least 
−4 %) and LDL-cholesterol (LDL-C, about −6 %) [13, 
15–17]. In addition, dietary intake of soy protein reduced 
body weight in overweight and obese subjects, compared 
to diets containing animal protein [18, 19], although data 
on soy protein impact on overall fat mass reduction and 
abdominal adipose changes [20], as well as on circulating 
adipokine levels [21], are scanty and controversial.
The majorities of published studies on soy protein have 
evaluated the effect of purified protein included in the daily 
diet, without changes of the percent caloric intake from 
protein.
It should be, however, pointed out that patients do not 
eat nutrients such as purified soy protein; thus, an approach 
based on whole soy foods, possibly commercially availa-
ble, appears to be most desirable [22]. It must be, however, 
noted that in other conditions, the whole soy food approach 
has shown differences in effects when compared to the iso-
lated components [23]. To our knowledge, the effects of 
commercially available whole soy foods on the cardiometa-
bolic parameters of the metabolic syndrome have never 
been evaluated. The present study, with an RCT design, 
aimed to assess the effects of a low-lipid diet with whole 
soy foods, on abdominal adipose tissue and related adi-
pokines, lipid/lipoprotein profiles and glucose metabolism, 
and to compare them with the effects of standard low-lipid 
diet with animal protein.
Materials and methods
Ethical issues
The study was conducted in accordance with the guide-
lines of the Declaration of Helsinki and its later amend-
ments. The study was approved by the ethics commit-
tee of A.S.S.T Grande Ospedale Metropolitano Ospedale 
Niguarda (approval no 170_04/2012).
Study design and population
The study was performed at the Centro Dislipidemie 
(A.S.S.T Grande Ospedale Metropolitano Ospedale 
Niguarda, Milan, Italy) in the period March 2013–June 
2015 following a randomized, parallel, controlled, single-
center design. Study subjects were followed at the Centro 
Dislipidemie and were used to consume a lipid-lowering 
diet. Inclusion criteria were: males and postmenopausal 
females aged between 45 and 75 years; BMI within the 
25–30 kg/m2 range; and LDL-C levels in the 130–190 mg/
dL range. Additionally, volunteers had to fulfill 3/5 features 
of the metabolic syndrome criteria, namely waist circum-
ference (WC) ≥102 cm (M) or ≥88 cm (F); blood pressure 
(BP) ≥130/85 mmHg; fasting glycemia (FPG) ≥100 mg/
dL; triglycerides (TG) ≥150 mg/dL; HDL-C <40 mg/dL 
(M); and <50 mg/dL (F) [24]. All study subjects fulfilled 3 
or 4 MetS criteria; none met all 5 criteria.
The exclusion criteria were: the presence of chronic liver 
disease, renal disease or severe renal impairment, untreated 
arterial hypertension, obesity (BMI ≥30 kg/m2), any past 
history of cerebro-vascular accident or coronary events, 
including unstable angina, myocardial infarction, percu-
taneous transluminal coronary angioplasty, or coronary 
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artery bypass graft; subjects affected by any kind of food 
allergy; any concomitant therapy known to alter any of the 
parameters to be assessed; history of or current alcohol or 
drug abuse; any clinically significant medical condition 
that could interfere with the conduct of the study; known or 
suspected diagnosis of hepatitis or HIV infection; subjects 
unable or unwilling to comply with the protocol require-
ments, or deemed by the investigator to be unfit for the 
study; and patients who were enrolled in another research 
study in the last 90 days. All patients were in primary pre-
vention, were free from liver/kidney disorders potentially 
affecting the response to treatment and did not take any 
drug affecting lipid/lipoprotein or glycemic profile, includ-
ing thiazolidinediones or corticosteroids. Concomitant 
medications are reported in Table 1.
Clinical evaluations
Clinical and biochemical evaluations were performed at 
the beginning and at the end of the treatment period. At all 
visits, patients underwent a fasting venous blood sampling 
and a full clinical examination, including the evaluation of 
height, body weight, heart rate and arterial blood pressure. 
The ViScan device (Tanita Inc., Tokio, Japan) is a validated 
tool to assess waist circumference (WC) [25] and abdomi-
nal fat mass [26, 27] by bioelectrical impedance analysis 
(BIA). WC was measured by the ViScan device (supine 
position, WCViScan) and by means of a non-stretchable tape 
at the umbilical level (standing position, WC). Hip circum-
ference (HC) was assessed by tape. ViScan was also used 
to evaluate bioelectrical impedance analysis (BIA) % and 
visceral fat rating (VFR) %. The reproducibility of ViScan 
was measured with a rigid human phantom (waist 65 cm, 
hip 90 cm).
All visits were performed by the same investigator 
(PM), and all ViScan analyses were conducted by the same 
operator (RB). Plasma samples were prepared by low-
speed centrifugation, and aliquots were immediately stored 
at −20 °C for subsequent assays. Safety and compliance 
information were collected at each visit, also by means of 
24-h dietary recalls, relative to 3 non-consecutive days for 
each month of nutritional intervention. Data retrieval, anal-
ysis and manuscript preparation were solely the responsi-
bility of the authors.
Intervention
After enrollment, they were instructed to follow a nor-
mocaloric/low-lipid diet, designed according to the Medi-
terranean diet criteria [28], with three main meals and two 
snacks and adapted to individual preferences in order to 
improve patient compliance. Extra virgin olive oil in mod-
erate quantity was suggested as topping. Dietary plans were 
defined with the aid of a dedicated software (Dietosystem, 
DS Medica srl, Milan, Italy). Diet composition was dif-
ferent for male and female subjects as shown in Table 2. 
Subjects were then randomly assigned to receive either the 
experimental diet, containing whole soy foods correspond-
ing to 30 g/day soy protein in substitution of animal foods 
containing the same amount of protein, or the control diet 
containing the animal foods, for 12 weeks (Fig. 1). The 
total daily amount of protein was 1 g/kg for all diets. In 
order to have a constant total energy intake over the inter-
vention period, personalized recommendations were given 
to each participant during each visit, according to three 
24-h dietary recalls.
Table 1  Concomitant medications (unchanged over the entire study 
duration)
Medication Patients (%)
ACE-I/ARB 1.9
Beta blockers 9.4
Diuretics 22.6
Calcium antagonists 1.9
Allopurinol 1.9
Proton-pump inhibitors 13.2
Other drugs 47.2
Table 2  Energy and 
macronutrient content of the soy 
food diet and the control diet 
used in the study
Variable Soy Control
Male Female Male Female
Energy (kcal/d) 1809.2 1520.5 1770.4 1493.0
Carbohydrate (g/d) 261.4 (54.2 %) 209.4 (51.6 %) 270.5 (57.3 %) 223.8 (56.2 %)
Protein (g/d) 77.1 (17.0 %) 56.7 (14.9 %) 70.6 (15.9 %) 62.6 (16.8 %)
Total fat (g/d) 55.8 (27.8 %) 54.5 (32.3 %) 52.8 (26.8 %) 44.8 (27 %  %)
Saturated fat (g/d) 7.5 8.5 10.4 7.3
Unsaturated fat (g/d) 17.2 15.8 6.7 5.3
Monounsaturated fat (g/d) 25.8 26.5 30.7 28.7
Cholesterol (mg/d) 21.2 7.6 100.5 113.4
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Characteristics of the soy diet
The soy diet was composed by different commercial soy 
foods from a portfolio including soy nuggets, soy burgers, 
soy desserts (different flavorings) and soy drinks (different 
flavorings), all provided by Alpro (Belgium). The composi-
tion of these products is shown in supplementary Table S1. 
In order to reach the necessary daily intake of soy foods, 
corresponding to 30 g soy protein, the subjects should con-
sume 3–4 servings per day, distributed in different meals 
as indicated in supplementary Table S2 for a better compli-
ance. At the beginning of each month, each subject received 
at home a bag containing all the soy foods necessary for the 
following 30 days.
Biochemical and immunometric assays
In each blood sample, total cholesterol (TC), TG, HDL-
C, lipoprotein(a) (Lp(a)), apolipoprotein (apo)A-I, apoB, 
C-reactive protein (CRP), fasting glycemia (FPG), aspar-
tate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyl transpeptidase (GGT) and creatine 
phosphokinase (CPK) were measured according to stand-
ard clinical procedures. LDL-C was calculated according 
to the Friedewald equation. Non-HDL-C was calculated 
as TC minus HDL-C [29]. Commercial enzyme-linked 
immunosorbent assay (ELISA) kits were used according 
to manufacturer’s specifications and previously published 
protocols to quantify plasma leptin [30], adiponectin, solu-
ble intercellular adhesion molecule-1 (sICAM-1), PCSK9 
(all from R&D System [31], Minneapolis, MN) and insu-
lin (Mercodia, Uppsala, Sweden). The Homeostasis Model 
Assessment of Insulin Resistance (HOMA) index was cal-
culated. The plasma concentration of HDL particles con-
taining only apoA-I (LpA-I) and of particles containing 
both apoA-I and apoA-II (LpA-I:A-II) was determined by 
electroimmunodiffusion in agarose gel using a commercial 
kit (Sebia, Lisses, France) [32]. The content of discoidal 
prebeta-migrating HDL was evaluated by non-denaturing 
two-dimensional electrophoresis followed by immunode-
tection against human apoA-I [33]. The content of prebeta-
HDL was calculated as percentage of total apoA-I signal. 
HDL subclass distribution according to particle size was 
determined by non-denaturing polyacrylamide gradient gel 
electrophoresis (4–30 %) of the d < 1.21 g/mL plasma total 
lipoprotein fraction; the protein-stained gels were scanned 
with an imaging densitometer to determine particle size 
and HDL were divided into small (diameter 7.2–8.2 nm), 
medium (diameter 8.2–8.8 nm) and large (diameter 8.8–
12.7 nm) particles [32]. Densitometric analyses were per-
formed with the GS-690 Imaging Densitometer and the 
Multi-Analyst software (Bio-Rad Laboratories, Hercules, 
CA).
Chemicals for isoflavones analysis
Daidzein (97 % purity) and genistein (97 % purity) were 
from Lancaster Synthesis (Morecambe, UK); deuterated 
daidzein (2′,3′,5′,6′-d4, 98 % purity), deuterated genistein 
(2′,3′,5′,6′-d4, 98 % purity) and equol (≥98 % purity) were 
from Cayman Chemicals (Milan, Italy). Dihydrogenistein 
(DHG, 98 % purity) was from Alfachem (Milan, Italy). 
The hydrolytic enzyme mixture containing sulfatase and 
β-glucuronidase from Helix pomatia (glucuronidase activ-
ity 400 units/g, sulfatase activity less than 40 units/g), 
sodium citrate, ammonium bicarbonate and methanol was 
from Sigma-Aldrich (Milan, Italy).
Isoflavone extraction from human serum 
and HPLC-CHIP ESI–MS analysis
The extraction of isoflavones and their metabolites was 
performed according to our published method [34]. The 
quantitative analysis was performed using an Agilent 1200 
Series Nanoflow LC system. The Agilent HPLC-Chip/MS 
was interfaced to an Agilent SL series ion trap (Agilent, 
CA). The intra-assay variations reported as RDS  % were 
within the range 1.8–6.7 % (Table 6). For more details, see 
Supplementary Materials and Methods.
Sample size and statistical analysis
Results are presented as median and interquartile ranges 
(Q1 and Q3) for all parameters. The differences from 
treatment arms at baseline were assessed by Wilcoxon-
rank sum test. Chi-square test was applied to evaluate the 
difference in frequencies among arms. The difference by 
treatment arms as changes from baseline [12-week treat-
ment–baseline (0 week)] was evaluated by ANCOVA 
adjusted for baseline, age and sex. Data were also 
-4 12weeks
-1 2visits
control diet
whole soy food diet
R
R = randomizaon
0
0
Fig. 1  Schematic representation of the trial design
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expressed as median of changes between [12-week treat-
ment and baseline (0 week)] and quartiles (supplemen-
tary Table S3). Residuals from full models, investigating 
factors variations, were checked to assess normal distri-
bution. Principal components analysis was performed, 
and the scree plot of ordered eigenvalues of a correlation 
matrix was used to decide the appropriate number of fac-
tors extracted. Only variables with loading ≥0.40 were 
considered for interpretation. Finally, we checked whether 
the scores of factors obtained were significantly different 
between the two treatment arms. Statistical analysis was 
performed by using the SAS software v. 9.2 (SAS Inc., 
Cary, NC). A group sample size of 26 per arm achieves 
80 % power to detect a difference of 20 mg/dL in absolute 
changes (12–0 week) in LDL levels (mg/mL) between the 
null hypothesis that both arms means of change in LDL 
are 10 mg/mL and the alternative hypothesis that the mean 
of change in LDL in the treatment arms is −10.0 mg/mL 
with estimated group standard deviations of 25.0 mg/mL 
per arm and with a significance level of 5 % using a two-
sided two-sample t test.
Results
Study population
After a run-in period of 4 weeks on a balanced low-lipid 
diet, only subjects showing changes in total cholesterol 
<10 % were recruited for the study. Sixty-two subjects (32 
M, 30 F) were assessed for eligibility, 6 were excluded, and 
56 (29 M, 27 F) were enrolled into the study and randomly 
allocated to either the soy diet (N = 28; 14 M, 14 F) or the 
control diet (N = 28; 15 M, 13 F), for a total intervention 
duration of 12 weeks. Of them, 27/28 subjects completed 
the control diet arm and 26/28 completed the soy diet arm 
(Fig. 2). Wilcoxon-rank sum test indicates that at baseline 
all clinical and biochemical values, including lipids, adi-
pokines and inflammatory markers, were similar between 
the two treatment arms (Table 3). Fifty-three volunteers, 
gender and age matched, were included, and 13.2 % of 
them were smokers. Men were 55 % in the control arm 
and 50 % in the soy arm; median age was 60 years in 
both arms. As reported in Table 4, BMI (27.3 kg/m2 in the 
Assessed for eligibility 
(n=62)
Excluded (n=6)
Lipid values out of range (n=6)
Allocated to control intervenon (n=28)
Received allocated 
intervenon (n=28)
Did not receive allocated
intervenon; personal dues (n=1)
Analysed (n=27)
Excluded from analysis (n=0)
Allocated to soy intervenon (n=28)
Received allocated 
intervenon (n=28)
Did not receive allocated
intervenon; non-compliant (n=2)
E
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t
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s
Entered 4 weeks run-in period 
before randomizaon 
(n=56)
Excluded (n=0)
Randomized to one of the two groups 
(n=56)
Analysed (n=26)
Excluded from analysis (n=0)
Fig. 2  Consort flow diagram
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control group and 28.2 kg/m2 in the soy group) indicated 
that study subjects were overweight with a relevant abdom-
inal adiposity, as evaluated by WC, WCViscan (104 cm in 
the control group and 105 cm in the soy group), HC and 
WC:HC ratio (1.00 in both arms). Subjects also had a mod-
erate dyslipidemia and met 3 or 4 out of 5 MetS criteria. 
No signs of hypertension (SBP, 125 mmHg in both arms) 
and of relevant systemic low-grade inflammation (CRP, 
0.2 mg/dL in both arms) were detected.
Effect of soy diet
At the end of the treatment period, 50 % (13/26) of sub-
jects on soy food showed a reduction in the number of 
MetS features. In the control group, 26 % (7/27) of sub-
jects showed a reduction in MetS feature number. The dif-
ference in frequencies (Chi-square test) among arms was 
p = 0.094. A significant reduction in weight (median per-
centage change: −1.5 %; p = 0.005) and BMI (median 
percentage change: −1.5 %; p = 0.05), after adjustment 
for age and sex, was noted in the soy food arm (Table 4). 
No differences were instead recorded between the two 
groups for abdominal adipose tissue variables (WC, HC, 
WC:HC, BIA % and VFR %) and related adipokines, 
namely leptin and adiponectin. This lack of significant 
changes in visceral adipose and related biomarkers was 
paralleled by unaffected glucose metabolism (FPG, insu-
lin and HOMA) and inflammation (sICAM-1 and CRP) 
parameters.
A 12-week (wk) lipid/lipoprotein changes were charac-
terized by significantly reduced TC (p = 0.002), LDL-C 
(p = 0.01) and non-HDL-C (p = 0.007) in the soy food 
group versus the control group, with median percent-
age changes for TC = −4.85 %, LDL-C = −5.25 % and 
non-HDL-C = −7.14 %. These were not linked to BMI 
changes as assessed by ANCOVA adjusted for the con-
founding factors; p values were 0.10 for TC, 0.45 for 
LDL-C and 0.08 for non-HDL-C. Conversely, these 
lipid markers showed a percentage median increment 
(TC = 4.6 %, LDL-C = 5.7 % and non-HDL-C = 4.2 %) 
in the control group. Overall, results were not influenced 
by median changes recorded during the 4-week run-in 
period (−4 and 0 week). Specifically, these were +4.2 mg/
dL (p = 0.78) for TC; −1.7 mg/dL (p = 0.57) for LDL-C; 
and +4 mg/dL (p = 0.88) for non-HDL-C. ApoB, apoAI 
and LpA-I levels were also significantly modified by soy 
food consumption. Percentage changes of these param-
eters were −14.8 % (apoB; p = 0.019), −5 % (apoAI; 
p = 0.008) and −3.8 % (LpA-I; p = 0.02). No significant 
differences were found between the two groups for TG, 
Lp(a) and PCSK9 values.
Plasma levels of HDL-C and HDL subclass distribution 
(discoidal pre-migrating HDL, small, medium and large 
HDL, HDL2, HDL3), as well as that of apoA-I-containing 
HDL subclass LpA-I:A-II, were not modified by soy food 
consumption (supplementary Table S4).
Table 3  Main baseline clinical and biochemical characteristics of the 
study population
Values are expressed as median (interquartile range, Q1 and Q3). p 
values were assessed by Wilcoxon-rank sum test and represent differ-
ences between median values at baseline between the two arms
SBP Systolic blood pressure, DBP diastolic blood pressure, HR heart 
rate, BMI body mass index, WC waist circumference, HC hip circum-
ference, BIA bioelectrical impedance analysis, VFR visceral fat rat-
ing, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, 
HDL-C high-density lipoprotein cholesterol, TG triglycerides, Lp(a) 
lipoprotein (a), apoB apolipoprotein B, apoA-I apolipoprotein A-I, 
FPG fasting plasma glucose, sICAM-1 soluble intercellular adhesion 
molecular 1, CRP high-sensitivity C-reactive protein
Parameter Value p value
No. of participants  
(men/women)
53 (28/25) –
Smokers, n (%) 7 (13.2) –
Age, years 58.9 (55.5, 66.3) 0.89
SBP (mmHg) 125 (120, 132.5) 0.20
DBP (mmHg) 80 (77.5, 87.5) 0.85
HR (bpm) 66 (64, 74) 0.97
Weight (kg) 76.0 (69, 81) 0.51
BMI (kg/m2) 27.8 (25.8, 29.6) 0.31
WCTAPE (cm) 97.0 (93.5, 103.5) 0.26
HCTAPE (cm) 99.0 (94, 102) 0.56
WCTAPE:HCTAPE 1.0 (0.9, 1.0) 0.31
WCVSCAN (cm) 104.5 (9.7, 113) 0.98
BIA (%) 40.6 (34, 45.8) 0.67
VFR (%) 13.0 (11.3, 17.0) 0.86
Leptin (ng/mL) 14.2 (6.8, 22.4) 0.31
Adiponectin (µg/mL) 5.9 (4.4, 9.7) 0.68
Leptin:adiponectin 2.1 (1.2, 3.3) 0.09
TC (mg/dL) 254.2 (227.5, 274.6) 0.42
LDL-C (mg/dL) 168.0 (141.8, 186.5) 0.57
HDL-C (mg/dL) 45.6 (38.5, 50.5) 0.52
Non-HDL-C (mg/dL) 208.1 (186.1, 231.2) 0.36
Lp(a) (mg/dL) 16.0 (6.0, 25.0) 0.61
TG (mg/dL) 193.0 (143.3, 240.4) 0.37
ApoB (mg/dL) 155.0 (141.5, 172) 0.11
ApoA-I (mg/dL) 115.0 (110, 123.5) 0.63
PCSK9 (ng/mL) 289.6 (243.6, 333.6) 0.66
ApoB:apoA-I 1.3 (1.2, 1.5) 0.36
ApoB:PCSK9 0.54 (0.4, 0.6) 0.06
FPG (mg/dL) 94.0 (87.3, 104.1) 0.37
Insulin (mU/L) 7.66 (6.2, 14.0) 0.61
HOMA-IR 1.9 (1.4, 3.8) 0.48
sICAM-1(ng/mL) 260.2 (230, 294.) 0.36
CRP (mg/dL) 0.187 (0.1, 0.3) 0.81
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Factor analysis
Since the majority of the studied variables were strongly 
correlated, to reduce them to a smaller set of latent or 
underlying independent factors, factor analyses were 
applied. Three factors were identified which explained the 
majority (52 %) of the total variance in the whole data set. 
As shown in Table 5, the factor with the highest loading 
scores (≥0.40), which were those describing lipid and adi-
pose features, was the most influential factor explaining the 
22 % of the total variance (52 %) (factor 1). In particular, 
the lipid parameters were described by TC (loading score 
0.87), apoB (loading score 0.77), LDL (loading score 0.64) 
and the adipose ones by BMI (loading score 0.52), total 
abdominal fat (BIA %, loading score 0.44) and abdominal 
cavity (VFR %, loading score 0.41). Factor 2 had positive 
loading of HOMA (0.79) and insulin (0.72) and a negative 
one of BIA % (−0.68) and VFR % (−0.60). The third fac-
tor was characterized by positive loadings for WC (0.71) 
and HC (0.51) (Table 6). Notably, we found that scores of 
obtained factors were significantly different between the 
two treatment arms only for factor 1 (p = 0.002, corrected 
for age and sex) (Fig. 3).
Safety, tolerability and compliance
The nutritional intervention with either soy or control food 
items for 12 weeks was well tolerated by all participants, 
and no specific adverse effects were reported. No changes 
in liver function and thyroid parameters were detected after 
the nutritional intervention with soy foods, which were 
Table 5  Results of factor analysis of all studied subjects
Factors
1 2 3
TC 0.87 0.25 −0.09
ApoB 0.77 0.26 −0.17
LDL 0.64 0.18 0.05
BMI 0.52 −0.34 0.31
apoAI 0.43 0.27 0.05
WCvscan 0.41 −0.22 −0.08
Leptin 0.40 −0.09 0.10
Non-HDL-C −0.43 −0.10 0.24
HOMA 0.09 0.79 0.20
Insulin −0.01 0.72 0.29
FPG 0.27 0.40 −0.17
VFR (%) 0.44 −0.60 −0.01
BIA (%) 0.47 −0.68 0.17
WC 0.26 −0.12 0.71
HC 0.14 0.03 0.55
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well accepted by all subjects. The compliance toward both 
diets was well above 95 %, according to food diary analy-
sis. To assess the compliance, circulating isoflavones and 
their metabolites were quantified in the soy food group sub-
jects. Isoflavone concentrations at baseline were under the 
LOD or LOQ of the analytical method (data not shown). 
At the end of the dietary intervention, quantifiable amounts 
of daidzein were detected in 25 subjects, of genistein in 22 
subjects, of DHG in 2 subjects and of DHD in 1 subject, 
whereas equol remained always under the limit of quanti-
fication (Table S5). Hence, patients were clustered accord-
ing to different metabolic pathways. One male (cluster A) 
did not show any quantifiable metabolite, since even daid-
zein and genistein, the two main isoflavones, were under 
the LOQ. In subjects (2 M and 2 F) included in cluster B, 
only daidzein was quantifiable with concentrations rang-
ing between 0.063 and 0.253 µM, whereas in subjects (9 
M and 9 F) included in cluster C it was possible to detect 
either daidzein, in the range from 0.010 to 0.722 µM, or 
genistein, in the range between 0.007 and 0.328 µM. One 
female (cluster D) besides daidzein and genistein showed 
also DHD, a metabolite of daidzein (0.066 µM), while in 2 
subjects (1 M and 1 F; cluster E), serum contained DHG, 
a metabolite of genistein, at concentrations of 0.070–
0.124 µM as well as daidzein and genistein (Table 6).
Discussion
The reduction in metabolic and consequent CV risks by an 
appropriate nutritional approach has been widely addressed 
in the last decades. Different strategies, such as the imple-
mentation of traditional habits (Mediterranean diet [28] or 
Far East traditional diets [35]), novel functional foods [36] 
and nutraceuticals [10], have been described. The asso-
ciation of soy protein consumption with reduced CV risk, 
mainly by way of TC and LDL-C lowering, is well estab-
lished [13, 37] and has led to a health claim approval by the 
FDA for coronary heart disease risk reduction [38].
A large number of data are available on the effects of 
purified soy protein on lipid parameters, generally obtained 
from human studies substituting 25–30 g/day protein from 
animal sources with an equal amount of soy protein pro-
vided in model foods [13], whereas the effects of commer-
cially available whole soy foods have not been fully evalu-
ated. Today, it appears of growing importance moving from 
studies on isolated nutrient effects toward RCTs evaluating 
whole foods [39]. Further, scanty data are available on the 
impact of soy-based dietary plans on novel metabolic and 
CV risk factors [40], such as body size variables (body 
weight and abdominal fat), insulin resistance biomarkers 
and adipokines.
The present 3-month intervention study, designed fol-
lowing the FDA recommended intake of soy protein (25–
30 g/day) [38], specifically evaluated commercially avail-
able whole soy foods. The study was conducted in subjects 
with moderate dyslipidemia and MetS carriers, also 
attempting to replicate the large number of data on isolated 
soy proteins in a seldom studied patient population.
The soy food diet significantly improved the plasma 
lipid profile, regardless of age, sex and baseline values, 
with significant median reductions in TC (−4.8 %), LDL-C 
(−5.2 %), non-HDL-C (−7.1 %) and apoB (−14.8 %), in 
line with most clinical trials evaluating the effect of the use 
of soy protein concentrates or isolates [13, 14, 17]. Moreo-
ver, these changes were not correlated with those of BMI, 
thus indicating that the lipid-lowering effect is independent 
of weight loss.
Of note, both apoB and non-HDL-C have been reported 
to be superior to LDL-C as markers of CV risk [29]. Being 
apoB synthesized by the liver and reflecting the total num-
ber of chylomicrons, VLDL, intermediate density lipo-
protein and LDL particles, it better reflects the total ath-
erogenic burden than LDL-C [33]. Similarly, non-HDL-C 
accounts for all atherogenic lipoproteins and recent data 
from a large series of studies confirmed it to be a better CV 
risk predictor than LDL-C in both primary and secondary 
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prevention [23, 34]. Remarkably, a significant median 
reduction in non-HDL-C (−7.1 %, Fig. 4) occurred in the 
soy group. The apoB:apoA1 ratio was instead unchanged. 
A reduction in the CV/metabolic risk by the soy food diet 
may also be secondary to the median body weight and BMI 
changes (−1.5 % for both).
It is well known that MetS criteria take into account WC, 
which, along with other anthropometric measures (e.g., 
WHR, waist-to-height ratio, sagittal depth), better reflects 
the amount of visceral adipose tissue [41], although BMI in 
itself is a strong predictor of CV risk and overall mortality 
[42]. In order to understand the effects of soy foods on the 
classical MetS features, a factor analysis was applied. This 
represents a multivariate correlation technique which reduces 
a large number of interrelated variables to a smaller set of 
latent or underlying independent factors. Thus, the factor 
analysis has the potential to clarify the complex pathophysi-
ological and statistical interactions underlying the MetS. 
Loadings are continuously distributed correlations, higher 
loadings indicating stronger associations between measured 
variables and associated factors [43]. In our cohort, among 
the three factors behind the overall correlation amidst risk 
variables, we found that adiposity parameters, either general 
or central, loaded on all three factors, implying that obesity 
is the link that unifies the MetS. Interestingly, our data are 
in accordance with those reported by Anderson [44] describ-
ing how, in a cohort of different ethnicity (Hong Kong Chi-
nese subjects), adiposity (both central and general) was the 
common link between the major facets of MetS. Since the 
MetS is a condition also characterized by increased visceral 
fat accumulation, it can be hypothesized that an imbalance 
in the secretion of adipokines may be related to some of the 
metabolic abnormalities. In our cohort, leptin was highly 
correlated only with factor 1 (related to lipid and adipose 
features) characterized by high positive loadings for BMI 
and WCViScan. This finding is in line with previous studies 
indicating that leptin is positively correlated with BMI, but 
does not link features of MetS [45–47].
Along with the well-known effect of soy on lipid param-
eters, a recent meta-analysis on randomized controlled 
studies [48] failed to show a significant body weight reduc-
tion in MetS patients. Our nutritional intervention led to an 
important improvement of factor 1 (lipid and adiposity fea-
tures), describing 22 % of the total variance. This indicates 
that this nutritional approach can improve, in MetS sub-
jects, both lipid and adiposity parameters, and, to a lesser 
extent, glucometabolic indices (FPG, insulin and HOMA), 
as described by factor 2 (Fig. 2). Further, in the soy group, 
a reduction in MetS feature numbers was observed in 50 % 
of the subjects, thereby lowering their overall cardiometa-
bolic risk.
A satisfactory compliance to the dietary interven-
tion was supported by the isoflavone analyses. It is well 
known that in soybean and in unfermented soy foods, iso-
flavones are present as β-glucosides [49], not absorbed 
at the intestinal level. After ingestion, however, the gly-
cosidic bond is hydrolyzed by the microbiota to release 
free aglycones, which may be either absorbed or further 
metabolized, mostly by microbiota. These metabolic steps 
include the conversion of daidzein to dihydrodaidzein 
(DHD), equol and O-desmethylangolensin (O-DMA), 
whereas genistein is converted to dihydrogenistein (DHG) 
[50]. After absorption, the aglycones are again conjugated 
with glucuronic acid and, to a smaller extent, sulfate, or 
bound to plasma proteins, such as albumin. Conjugated 
forms follow the enterohepatic circulation and may be 
excreted, primarily in urines [51]. Isoflavones and their 
metabolites were detected in sera of all soy group partici-
pants, with only one exception. This does not rule out soy 
food consumption by this subject: many variables influ-
ence absorption and metabolism of isoflavones and inter-
individual variations in gut microbiota have a major role 
in formation, absorption and/or metabolism of free agly-
cones [50, 51].
Major limitations of the present study were the intrin-
sic impossibility to implement a double-blind design, in 
order to avoid personal preferences toward the different 
foods, and the fact that the selected women were all post-
menopausal, at greater metabolic and CV risk. The major 
strength, instead, was the validation of a dietary approach 
based on commercially available whole soy foods, allow-
ing to achieve a better compliance and providing positive 
outcomes on some metabolic risk biomarkers.
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